The Humanistic Burden of Advanced Non-Small Cell Lung Cancer Patients in Europe - A Real World Survey

被引：0
|
作者：
Taylor-Stokes, Gavin [1 ]
Wood, Robert [1 ]
Malcolm, Bill [2 ]
Lees, Michael [3 ]
Chirita, Oana [2 ]
机构：
[1] Adelphi Real World, Bollington, England
[2] Bristol Myers Squibb, Uxbridge, Middx, England
[3] Bristol Myers Squibb, Rueil Malmaison, France
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
NSCLC; humanistic burden; quality of life; Real world;
D O I：
10.1016/j.jtho.2016.11.896
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.06-032
引用
收藏
页码：S685 / S685
页数：1
相关论文
共 50 条
  • [41] Real-world patient characteristics and treatment patterns in US patients with advanced non-small cell lung cancer
    Divan, Hozefa A.
    Bittoni, Marisa A.
    Krishna, Ashok
    Carbone, David P.
    BMC CANCER, 2024, 24 (01)
  • [42] Real-World Experience With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer at Frankfurt University Hospital
    Shaid, S.
    Stratmann, J.
    Wolf, A.
    Niklas, N.
    Calleja, A.
    Munro, R.
    Waldenberger, D.
    Carroll, R.
    Daumont, M.
    Penrod, J.
    Lacoin, L.
    Rohde, G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1003 - S1004
  • [43] Real-world clinical characteristics and treatment of advanced non-small cell lung cancer (NSCLC) patients in China
    Shi, Yuankai
    Zhang, Xin
    Wu, Gang
    Xu, Jianping
    He, Yong
    Wang, Dong
    Huang, Cheng
    Chen, Mingwei
    Yu, Ping
    Yu, Yan
    Li, Wei
    Li, Qi
    Hu, Xiao-hua
    Sun, Guofang
    Li, Yulin
    Bu, Lilian
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [44] REAL WORLD USE OF MAINTENANCE CHEMOTHERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER IN AN AUSTRALIAN CANCER CENTRE
    Wann, A.
    Newnham, G.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S187 - S187
  • [45] The Real-World Efficacy and Safety of Anlotinib Treatment for Advanced Non-Small Cell Lung Cancer
    Wang, F.
    Jin, F.
    Wang, S.
    Zhu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S673 - S673
  • [46] Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: A Real-World Study
    Zhang, Kun
    Ma, Xiya
    Gao, Hongjun
    Wang, Hong
    Qin, Haifeng
    Yang, Shaoxing
    Liu, Xiaoqing
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 3409 - 3417
  • [47] A Real World Evidence of Lorlatinib for Taiwanese with advanced ALK Positive Non-Small Cell Lung Cancer
    Shih, J. -Y.
    Luo, Y. -H.
    Chang, G. -C.
    Chang, J. W. -C.
    Wang, C. -C.
    Yang, T.
    Fang, W.
    Shau, W. -Y.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S475 - S475
  • [48] A Real-World Study: Efficacy and Safety of Anlotinib for Advanced Non-Small Cell Lung Cancer
    Wang, J.
    Yi, T.
    Dong, Y.
    Ran, R.
    Cao, F.
    Li, Y.
    Luo, Z.
    Xu, Y.
    Fu, Y.
    Kuang, L.
    Chen, G.
    Qu, G.
    Yin, Y.
    Li, J.
    Xu, X.
    Chen, Y.
    Song, Q.
    Chu, Q.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1071 - S1071
  • [49] Nivolumab outcomes in interstitial lung disease patients with advanced non-small cell lung cancer in French real-world setting
    Assie, J-B.
    Chouaid, C.
    Nunes, H.
    Reynaud, D.
    Gaudin, A-F.
    Grumberg, V.
    Jolivel, R.
    Jouaneton, B.
    Cotte, F-E.
    Duchemann, B.
    ANNALS OF ONCOLOGY, 2021, 32 : S1418 - S1418
  • [50] The evolving diagnostic and treatment landscape in metastatic non-small cell lung cancer (mNSCLC) across Europe: A real world evidence survey
    Bailey, H.
    Lee, A.
    Eccles, L.
    Yuan, Y.
    Khela, K.
    Hall, J.
    Last, M.
    Varol, N.
    ANNALS OF ONCOLOGY, 2021, 32 : S1421 - S1421
12345